SIRO Clinpharm Pvt. Ltd. Revenue and Competitors

Mumbai, Ind

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • SIRO Clinpharm Pvt. Ltd.'s estimated annual revenue is currently $94.9M per year.(i)
  • SIRO Clinpharm Pvt. Ltd.'s estimated revenue per employee is $201,000

Employee Data

  • SIRO Clinpharm Pvt. Ltd. has 472 Employees.(i)
  • SIRO Clinpharm Pvt. Ltd. grew their employee count by -2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$56.6M56321%N/AN/A
#2
$15.6M15528%N/AN/A
#3
$17M169-11%N/AN/A
#4
$13.2M1318%N/AN/A
#5
$19.6M19510%N/AN/A
#6
$23.5M2347%N/AN/A
#7
$5.3M530%N/AN/A
#8
$13M129-25%N/AN/A
#9
$20.5M20411%N/AN/A
#10
$11.7M1166%N/AN/A
Add Company

What Is SIRO Clinpharm Pvt. Ltd.?

SIRO Clinpharm is an end to end, drug development solutions provider to the global healthcare industry.Our subject expertise gives us an edge in clinical trial management, clinical data management, medical writing, biostatistics and statistical programming, and pharmacovigilance. With a successful track record of 20 years, SIRO Clinpharm works with most top global biopharma and medical device companies. Our therapeutic experience includes – but is not limited to – oncology, diabetes, cardiology, infectious diseases and the respiratory system. We offer flexible business models across service verticals based on client needs. Our industry leadership has been widely recognised. We were named ‘Best Clinical Research Company’ of the year at the Healthcare and Fitness Leadership Awards 2016 organised by CMO Asia and Stars of the Industry Group. We are also two-time winners of the Frost & Sullivan ‘Indian Clinical Research Organization of the Year'’ award. Visit www.siroclinpharm.com to learn more about our services.

keywords:N/A

N/A

Total Funding

472

Number of Employees

$94.9M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$43.1M476-4%N/A
#2
$3.5M4778%N/A
#3
$61.1M477-1%N/A
#4
$43.2M477-18%N/A
#5
N/A4786%N/A